Vertex Pharmaceuticals Unveils New Data Highlighting Enhanced Quality of Life with ALYFTREK at European Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated has announced new data from multiple studies demonstrating positive clinical and quality of life benefits associated with the cystic fibrosis treatment ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor). The data, which was presented at the 48th European Cystic Fibrosis Conference held from June 4-7, 2025, in Milan, Italy, suggests that ALYFTREK is linked to improved health-related quality of life outcomes compared to TRIKAFTA®. The studies include both randomized, controlled and open-label trials. The findings indicate that reductions in sweat chloride levels achieved through treatment with CFTR modulators like ALYFTREK are correlated with better patient outcomes, including enhanced CF symptoms and general functioning in children aged 6-11 years. ALYFTREK is approved in the United States and United Kingdom, and is under review in other regions including the EU, Canada, Australia, New Zealand, and Switzerland.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20250606362203) on June 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.